Compare PSA & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSA | BDX |
|---|---|---|
| Founded | 1972 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.8B | 55.5B |
| IPO Year | N/A | 1962 |
| Metric | PSA | BDX |
|---|---|---|
| Price | $289.20 | $204.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $314.08 | $205.25 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 02-23-2026 | 02-04-2026 |
| Dividend Yield | ★ 4.08% | 2.03% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 9.63 | 5.82 |
| Revenue | $4,795,182,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $3.04 | $4.01 |
| Revenue Next Year | $3.44 | $3.38 |
| P/E Ratio | ★ $30.52 | $35.59 |
| Revenue Growth | 2.06 | ★ 8.24 |
| 52 Week Low | $256.54 | $162.29 |
| 52 Week High | $322.49 | $251.99 |
| Indicator | PSA | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 65.05 | 57.34 |
| Support Level | $273.70 | $198.44 |
| Resistance Level | $295.72 | $209.27 |
| Average True Range (ATR) | 6.40 | 4.27 |
| MACD | 3.44 | 0.40 |
| Stochastic Oscillator | 82.81 | 69.24 |
Public Storage is the largest owner of self-storage facilities in the US, with more than 3,300 self-storage facilities in 40 states and approximately 245 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage. The company also has a merchandise business, a third-party property management business, and an insurance business that offers products to cover losses for the goods in self-storage facilities.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.